% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mller:283132,
      author       = {Müller, Laura and Özdüzenciler, Pelin and
                      Schedlich-Teufer, Charlotte and Seger, Aline and Jergas,
                      Hannah and Fink, Gereon R and Willbold, Dieter and
                      Sommerauer, Michael and Barbe, Michael T and Tamgüney,
                      Gültekin},
      title        = {{E}levated α-{S}ynuclein {A}ggregate {L}evels in the
                      {U}rine of {P}atients with {I}solated {REM} {S}leep
                      {B}ehavior {D}isorder and {P}arkinson's {D}isease.},
      journal      = {Annals of neurology},
      volume       = {98},
      number       = {1},
      issn         = {0364-5134},
      address      = {Hoboken, NJ},
      publisher    = {Wiley-Blackwell},
      reportid     = {DZNE-2026-00028},
      pages        = {147 - 151},
      year         = {2025},
      abstract     = {Parkinson's disease (PD) is a neurodegenerative disorder
                      characterized by α-synuclein aggregation in neurons. Recent
                      advances suggest α-synuclein aggregates could serve as a
                      biomarker for PD and related synucleinopathies. This study
                      used surface-based fluorescence intensity distribution
                      analysis (sFIDA) to measure α-synuclein aggregates in
                      urine. Patients with PD and isolated rapid eye movement
                      sleep behavior disorder, a precursor to PD, had elevated
                      concentrations compared with healthy controls. Sensitivity
                      and specificity were $83\%$ and $65\%$ for PD versus
                      controls and $89\%$ and $62\%$ for isolated rapid eye
                      movement sleep behavior disorder versus controls. The
                      findings highlight sFIDA's potential for diagnosing
                      synucleinopathies. ANN NEUROL 2025;98:147-151.},
      keywords     = {Humans / Parkinson Disease: urine / Parkinson Disease:
                      diagnosis / REM Sleep Behavior Disorder: urine / REM Sleep
                      Behavior Disorder: diagnosis / alpha-Synuclein: urine / Male
                      / Female / Middle Aged / Aged / Biomarkers: urine /
                      Sensitivity and Specificity / alpha-Synuclein (NLM
                      Chemicals) / Biomarkers (NLM Chemicals)},
      ddc          = {610},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40285625},
      pmc          = {pmc:PMC12174725},
      doi          = {10.1002/ana.27250},
      url          = {https://pub.dzne.de/record/283132},
}